Seeking Alpha
12 Jul 2026, 17:21 UTC · 14w ago
Silence Therapeutics: PV Data Could Wake The Stock (Initiating Buy)
Impact · against what's priced in
Silence Therapeutics is positioned for a binary move based on the upcoming August 2026 Phase 2 readout for divesiran. While Phase 1 data and the dosing platform provide a bullish foundation, the stock's value currently depends on the successful clinical validation of its primary asset.
- SLN+0.60
No priced-in read yet
- In context
The upcoming August 2026 Phase 2 readout for divesiran in polycythemia vera serves as a near-term binary catalyst that could significantly re-rate the stock.
Read from the article alone
Top 1 mover · tap to explore
